WO2006132983A3 - Differential expression of molecules associated with vascular disease risk - Google Patents

Differential expression of molecules associated with vascular disease risk Download PDF

Info

Publication number
WO2006132983A3
WO2006132983A3 PCT/US2006/021491 US2006021491W WO2006132983A3 WO 2006132983 A3 WO2006132983 A3 WO 2006132983A3 US 2006021491 W US2006021491 W US 2006021491W WO 2006132983 A3 WO2006132983 A3 WO 2006132983A3
Authority
WO
WIPO (PCT)
Prior art keywords
molecules
risk
vascular disease
methods
differential expression
Prior art date
Application number
PCT/US2006/021491
Other languages
French (fr)
Other versions
WO2006132983A2 (en
Inventor
Alison E Baird
David F Moore
Ehud Goldin
Original Assignee
Us Gov Health & Human Serv
Alison E Baird
David F Moore
Ehud Goldin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv, Alison E Baird, David F Moore, Ehud Goldin filed Critical Us Gov Health & Human Serv
Publication of WO2006132983A2 publication Critical patent/WO2006132983A2/en
Publication of WO2006132983A3 publication Critical patent/WO2006132983A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/142—Toxicological screening, e.g. expression profiles which identify toxicity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

Methods are disclosed for using peripheral blood mononuclear cells to evaluate vascular disease, such as predicting a subject's risk of vascular disease, determining a treatment regimen for a subject who has such as risk, or combinations thereof. Also provided are arrays and kits that can be used to practice the methods. In one example, the method includes screening for differential expression of vascular risk-related molecules, such as DNA binding/transcription factor proteins, lysosomal or protein degradation enzymes, adhesion molecules, metabolism molecules, intracellular signaling molecules, immune response molecules, and apoptosis. Also provided are methods of screening agents to determine their affect on expression of vascular risk-related molecules.
PCT/US2006/021491 2005-06-03 2006-06-02 Differential expression of molecules associated with vascular disease risk WO2006132983A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US68751505P 2005-06-03 2005-06-03
US60/687,515 2005-06-03
US69173005P 2005-06-17 2005-06-17
US60/691,730 2005-06-17

Publications (2)

Publication Number Publication Date
WO2006132983A2 WO2006132983A2 (en) 2006-12-14
WO2006132983A3 true WO2006132983A3 (en) 2007-03-01

Family

ID=37451007

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/021491 WO2006132983A2 (en) 2005-06-03 2006-06-02 Differential expression of molecules associated with vascular disease risk

Country Status (1)

Country Link
WO (1) WO2006132983A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2598887B1 (en) * 2010-07-28 2015-08-19 Abbott GmbH & Co. KG Method for detection of ischemic strokes
WO2012054653A2 (en) * 2010-10-19 2012-04-26 Medtronic, Inc. Diagnostic kits, genetic markers, and methods for scd or sca therapy selection
WO2013137715A1 (en) * 2012-03-16 2013-09-19 Umc Utrecht Holding B.V. Biomarkers for adverse cardiac remodeling
EP3140429B1 (en) 2014-05-05 2020-02-19 Medtronic Inc. Methods for scd, crt, crt-d, or sca therapy identification and/or selection
CN108753834B (en) * 2018-05-28 2021-11-23 上海海洋大学 Preparation method of zebra fish mutant with ddx27 gene deletion

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"GeneChip Human Genome U133 set", ANNOUNCEMENT AFFYMETRIX, September 2001 (2001-09-01), XP002324895 *
BAIRD ALISON E ET AL: "Vascular biology: Cellular and molecular profiling", SEMINARS IN NEUROLOGY, vol. 26, no. 1, February 2006 (2006-02-01), pages 65 - 74, XP009075773, ISSN: 0271-8235 *
MOORE DAVID F ET AL: "Using peripheral blood mononuclear cells to determine a gene expression profile of acute ischemic stroke - A pilot investigation", CIRCULATION, vol. 111, no. 2, 18 January 2005 (2005-01-18), pages 212 - 221, XP002410085, ISSN: 0009-7322 *

Also Published As

Publication number Publication date
WO2006132983A2 (en) 2006-12-14

Similar Documents

Publication Publication Date Title
WO2006085984A3 (en) Immune cell biosensors and methods of using same
WO2006076025A3 (en) Immune cell biosensors and methods of using same
WO2006105252A3 (en) Diagnosis of chronic pulmonary obstructive disease and monitoring of therapy using gene expression analysis of peripheral blood cells
WO2006023412A3 (en) Biomarkers for osteoarthritis
WO2005123779A3 (en) Antibodies binding to cd34+/cd36+ fetal but not to adult cells
WO2008008846A3 (en) Differential expression of molecules associated with intra-cerebral hemorrhage
WO2005098445A3 (en) Lung cancer biomarkers
EP2535050A3 (en) Compositions and methods for detection of lysosomal storage disease
PL387691A1 (en) Urate oxidase variants and their application
WO2004011611A3 (en) Taci antibodies and uses thereof
WO2006132983A3 (en) Differential expression of molecules associated with vascular disease risk
NO20092741L (en) DR6 antagonists and their use in the treatment of neurological disorders
ATE540319T1 (en) METHOD FOR DETERMINATION OF FK506
WO2006076594A3 (en) Antibodies and fc fusion proteins with altered immunogenicity
WO2006066008A3 (en) Device and methods for identifying and treating aspirin non-responsive patients
WO2008088857A3 (en) Methods and compositions for detecting receptor-ligand interactions in single cells
ATE354674T1 (en) METHOD FOR DETECTING TRANSPLANT REJECTIONS
WO2005070086A3 (en) Methods and compositions for determining a graft tolerant phenotype in a subject
WO2009077864A3 (en) Compositions and methods of detecting tiabs
WO2006103639A3 (en) Methods and reagents for identifying/isolating t regulatory (treg) cells and for treating individuals
Philip et al. Dihydrofolate reductase 19-bp deletion polymorphism modifies the association of folate status with memory in a cross-sectional multi-ethnic study of adults
WO2007134818A3 (en) Method for diagnosing mitochondrial dysfunction
CA2366514A1 (en) Diagnostic and therapeutic use of antibodies against the urokinase receptor
WO2005036127A3 (en) Methods and compositions for identifying target cell cytolytic lymphocytes in a sample
WO2006089268A3 (en) Gene and cognate protein profiles and methods to determine connective tissue markers in normal and pathologic conditions

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06784552

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06784552

Country of ref document: EP

Kind code of ref document: A2